Target delivery of photo-triggered nanocarrier for externally activated chemo-photodynamic therapy of prostate cancer

2022 ◽  
Vol 23 ◽  
pp. 100688
Author(s):  
S. Ghosh ◽  
A.R. Gul ◽  
P. Xu ◽  
S.Y. Lee ◽  
R. Rafique ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Target Delivery

scholarly journals Selective Photodetection and Photodynamic Therapy for Prostate Cancer through Targeting of Proteolytic Activity

2012 ◽  
Vol 12 (3) ◽  
pp. 306-313 ◽  
Author(s):  
Maria-Fernanda Zuluaga ◽  
Nawal Sekkat ◽  
Doris Gabriel ◽  
Hubert van den Bergh ◽  
Norbert Lange
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Proteolytic Activity

scholarly journals Photodynamic therapy in the treatment of prostate cancer

2011 ◽  
Vol 2 ◽  
pp. 80-87 ◽  
Author(s):  
Andrzej M. Bugaj
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy

Focal Therapy of Prostate Cancer by Radiofrequency and Photodynamic Therapy

2013 ◽  
pp. 727-751
Author(s):  
Bob Djavan ◽  
Herbert Lepor ◽  
Reza Zare ◽  
Seyed Saeid Dianat
Keyword(s):  
Prostate Cancer ◽  
Photodynamic Therapy ◽  
Focal Therapy

scholarly journals Decision Regret and Quality of Life after Focal Therapy with Vascular-Targeted Photodynamic Therapy (TOOKAD®) for Localized Prostate Cancer

2021 ◽  
pp. 1-6
Author(s):  
Luka Flegar ◽  
Martin Baunacke ◽  
Bjoern Thorben Buerk ◽  
Rick Proschmann ◽  
Aristeidis Zacharis ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Prostate Cancer ◽  
Decision Making ◽  
Photodynamic Therapy ◽  
Local Recurrence ◽  
Post Treatment ◽  
Decision Regret ◽  
Targeted Photodynamic Therapy ◽  
Decisional Regret

<b><i>Purpose:</i></b> The aim of the study was to assess quality of life (QoL), decision involvement, and decisional regret after treatment with vascular-targeted photodynamic therapy (VTP) (TOOKAD®) for unilateral low-risk prostate cancer. <b><i>Methods:</i></b> Validated questionnaires (EORTC QLQ-C30 and QLQ-PR25) capturing QoL post-treatment, involvement in decision-making (Control Preferences Scale) and decision regret (Decisional Regret Scale), were given to patients at the 12-month visit after undergoing VTP at our institution between May 2018 and February 2021. <b><i>Results:</i></b> Out of 44 patients, 36 patients were included in this study and 31 (86.1%) responded to the questionnaires. Mean overall health score capturing QoL at 12 months was 79.3 (standard deviation: ±18.1). 70.9% of the patients (<i>n</i> = 22) had no decision regret, and 67.8% of men (<i>n</i> = 21) had an active role in decision-making. In control biopsy at 12 months post-treatment, 19.4% of patients (<i>n</i> = 7) presented with local recurrence and progression to higher Gleason score (GS) was found in 13.8% of patients (<i>n</i> = 5). Patients (<i>n</i> = 3) presenting with tumor recurrence or progression to higher GS in control biopsy showed a significantly higher level of decision regret (<i>p</i> &#x3c; 0.009). <b><i>Conclusion:</i></b> Only 9.7% of men (<i>n</i> = 3) felt a strong emotion of regret at 12 months after VTP. Level of decision regret was significantly higher in patients with local recurrence or tumor progression detected in control biopsy. QoL was stable after VTP.

scholarly journals Photodynamic therapy for prostate cancer: a systematic review and meta-analysis

2019 ◽  
Vol 7 (3) ◽  
pp. 83-90 ◽  
Author(s):  
Lang Wang ◽  
Hanfeng Yang ◽  
Bing Li
Keyword(s):  
Prostate Cancer ◽  
Systematic Review ◽  
Photodynamic Therapy ◽  
Meta Analysis
Sign in / Sign up

Export Citation Format

Share Document